Arben Ventures

www.arben.ventures

VCMatch tracks Arben Ventures as an investor focused on Digital Health, Biotech, and Medtech companies, Pre-Seed and Seed rounds, and $0 check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

Stages

Pre-Seed, Seed, Series A

Focus Areas

Digital Health, Biotech, Medtech

Geography

Not specified

Investment Thesis

Arben Ventures is a scientist-run, early-stage venture fund that focuses on translating transformative health innovations out of the lab and into companies. They target opportunities that are “too far along for academic support but too early for top VCs,” providing capital, domain expertise, and an operational community to help founders progress from research to commercial validation. The firm emphasizes hands-on partnership — weekly engagement, CEO masterminds, and strategic introductions — and measures success by follow-on funding, clinical milestones (e.g., FDA clearances), and building long-term networks between founders, scientists, and operators.

Is Arben Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Arben Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Digital Health, Biotech, Medtech, and AI/ML, with public check-size signals around $0.

Focus statement

Arben invests where "genomics, multi-omics, wearables, and AI converge to transform human health," backing early-stage founders solving the biggest problems in human health and "funding transformative ideas in health" that lie between academic support and larger VCs.

Value Add

Scientist-run fund: positions itself as "A venture fund run by scientists, backing early stage founders" (explicitly emphasizing scientific leadership).
Translational focus: targets the gap of ventures "too far along for academic support but too early for top VCs" and explicitly says "We bridge that gap — funding transformative ideas in health."
Domain concentration at the intersection of genomics, multi-omics, wearables, and AI (site: "Where genomics, multi-omics, wearables, and AI converge to transform human health").
Deep advisor and academic network, including Stanford Genetics leadership (Mike Snyder, PhD) and high-profile investors (e.g., Dave McClure), plus metrics like "Stanford Genetics World ranking in genomics" and 19k+ relationships.
Hands-on, community-first support: "Our engagement goes far beyond capital. We're in the trenches with founders every week," offering weekly CEO Mastermind, 200+ strategic introductions, 12 speaking placements, and $10M+ capital referred.
Proven early outcomes: portfolio metrics highlighted on the site (80+ portfolio companies, >$200M follow-on funding, and 3 FDA clearances) demonstrate translational and fundraising success.